… (PTC) offers excellent prognosis, however relapse risk or persistent disease is related to…
BRAF V600E mutation is such a marker. Many studies analyzing the prevalence of the mutation …

… We aim to investigate the risk factors that may predict the BRAF V600E mutation potential of
… 9,908 papillary thyroid carcinoma patients with average 74.6% BRAF V600E mutations were …

… : The BRAF V600E mutation is closely related to serum Tg elevation after treatment with
iodine-131 in papillary thyroid cancer. These findings suggest that this BRAF mutation may be a …

… BRAF V600E is detected in about half of PTC cases, … thyroid carcinoma, BRAF V600E
mutation has been shown to be associated with high risk clinicopathological characteristics, tumor …

… To investigate the mutant status of BRAF gene and analyze its relationship to epidemiological
risk factors and clinical outcomes among patients with papillary thyroid cancer (PTC) in the …

… targeted at the BRAF V600E mutation, BRAF V600E mutation testing by immunohistochemistry
should be considered in the routine histological evaluation of papillary thyroid carcinoma. …

… that the BRAF V600E mutation is associated with an increased risk of recurrence for patients
with papillary thyroid carcinoma. … The BRAF V600E mutation occurs in roughly 40–60% of …

… BRAF V600E mutation in papillary thyroid carcinoma (PTC) is controversial, the American
Thyroid Association (ATA) includes the mutational … of the BRAF V600E mutation status on PTC …

… Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.
Journal of Clinical Oncology 2015 33 42–50. (https://doi.org/10.1200/JCO.2014.56.8253) …

… meta-analysis to evaluate the associations between the BRAF V600E mutation status and
aggressive clinicopathological features and poor prognostic factors in papillary thyroid cancer. …